Xcovery Vision Presents VEGFR/PDGFR Oral Inhibitor X-82 Preliminary Data for Wet AMD at Association for Research in Vision & Ophthalmology

Published: May 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Xcovery Vision, a privately held biopharmaceutical company focused on creating the next generation of eye therapeutics, today presented preliminary data from the Phase I/II clinical trial of its dual VEGFR/PDGFR inhibitor, X-82, for the treatment of neovascular “wet” age-related macular degeneration (AMD) at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Help employers find you! Check out all the jobs and post your resume.

Back to news